Insider buying last 90 days
No open-market insider purchases were filed for IRON in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IRON insider filing, plotted on the chart in Gekko.Open IRON in Gekko
NASDAQ: IRON
Disc Medicine (IRON) Stock Analysis & Forecast
Oct 12 close
$60.48−1.58 (−2.5%)
Gekko Brief
AI summaryOct 12 closeDisc Medicine faces scrutiny this week after the FDA issued a Complete Response Letter regarding its bitopertin program, which the reporting linked to a 22% stock drop. Following that news, the Rosen Law Firm announced it is investigating potential securities claims on behalf of shareholders, with several related notices circulating. Separately, the company's Q3 2026 earnings date has been set for 5 November 2026, with analysts anticipating an EPS of -$1.63 and revenue of $1.88 million for the quarter.
IRON closed at $60.48, down 2.5%, sitting below both its 50-day average of $73.21 and its 200-day average of $71.11. Its one-month return stands at -13.7%, and it trades 22.8% below Gekko Fair Value of $78.34. The GekkoIndex reads 70.9, placing the stock in the Buying zone.
Over the next 20 trading days, the main event is the earnings report on 5 November 2026, 24 days away, which falls inside this typical holding window; the company's last reported EPS beat estimate, at -$1.54 versus a -$1.71 forecast, with a 4.5% reaction. Seasonality data shows the next 20 trading days have averaged a 13.6% gain across 5 years, rising in 5 of them. No insider, Congress, or unusual options activity appears in the current window, leaving smart-money positioning without a recent signal ahead of the print.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Disc Medicine price vs fair value
Close $60.48200-day averageGekko Fair Value $78.34
Disc Medicine quick facts
- Market cap
- $2.32B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$6.58
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 2.11
- Volume
- 648,354 avg 644,868
- 1-year return
- −14.5%
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±10.2%
- 50-day average
- $73.21
- 200-day average
- $71.11
- Next earnings
- Nov 5
- Shares outstanding
- 38.39M
Disc Medicine swing-trade checklist
Disc Medicine scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $60.48 sits between the 50-day ($73.21) and 200-day ($71.11) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
70.9, Buying
Reading 70.9 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
22.8% below
Price is 22.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+13.6% on average
From this point in the calendar, the next 20 trading days averaged +13.6% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Disc Medicine stock chart and price history
Disc Medicine closed at $60.48 on Oct 12, 2026, −14.5% over the past year, inside a 52-week range of $40.00 to $99.50.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −13.7%
- 3 months
- −19.4%
- 6 months
- −11.7%
- 1 year
- −14.5%
The full IRON chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IRON in Gekko
Follow Disc Medicine through every session
Put IRON on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IRON in GekkoFree for 7 days. No credit card required.
About Disc Medicine
Disc Medicine works in clinical-stage biotechnology, focused on finding, developing, and eventually bringing to market new treatments for people affected by serious blood-related diseases. The company has become known for building a slate of drug candidates aimed at these conditions, with particular attention to the biology of red blood cells, including how heme is produced and how the body manages iron levels.
Its work centers on assembling this pipeline of therapeutic candidates rather than selling approved products, with each program designed to intervene in a specific biological pathway tied to hematological illness. The company's efforts are directed at patients living with these serious blood disorders.
Disc Medicine is headquartered in Watertown, Massachusetts. Its shares are listed on the NASDAQ under the ticker IRON.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- discmedicine.com
Disc Medicine GekkoIndex: the smart money zone
Disc Medicine’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 70.9, in the Buying zone, down 0.3 points over five sessions.
70.9Buying
Down 0.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 37 | −1.5% | +3.1% | ||
| Accumulation | 189 | −0.1% | −0.7% | ||
| Neutral | 430 | +0.9% | +2.9% | ||
| Distribution | 23 | −4.1% | −4.6% | ||
| Selling | 3 | Too few readings yet | |||
Average IRON share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the IRON price, zone by zone.Track IRON in Gekko
Is Disc Medicine stock overvalued? Gekko Fair Value
Disc Medicine trades 22.8% below Gekko Fair Value of $78.34, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Disc Medicine shares are worth, recalculated every trading day.
$78.34
Gekko Fair Value, Oct 10, 2026
22.8% Undervalued
At the end of Aug 2026 the price was 15.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IRON in Gekko
Disc Medicine insider and Congress trading
No open-market insider purchases were filed for Disc Medicine, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IRON were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IRON, plotted on the chart in Gekko.Open IRON in Gekko
Disc Medicine earnings: next date and track record
Disc Medicine reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- −$1.63
- Revenue estimate
- $1.88M
5 of 8reports beat the EPS estimate
±3.2%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | −$1.54 est −$1.71 | — est $1.00M | +4.5% |
| May 5, 2026 | −$1.65 est −$1.78 | — est $438K | +1.5% |
| Feb 26, 2026 | −$1.64 est −$1.75 | — est $150K | −0.4% |
| Nov 6, 2025 | −$1.77 est −$1.48 | — | −5.1% |
| Aug 7, 2025 | −$1.58 est −$1.17 | — | −1.6% |
| May 7, 2025 | −$1.02 est −$0.99 | — | +4.0% |
| Feb 27, 2025 | −$0.98 est −$1.06 | — | +3.2% |
| Nov 12, 2024 | −$0.89 est −$0.98 | — | −5.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Disc Medicine stock forecast and analyst price targets
Analysts’ average 12-month price target for Disc Medicine is $103.17, +70.6% from the last close, from 11 firms rating the stock in the last 90 days.
$103.17consensus 12-month target, +70.6% from the last close
Now $60.48Avg $103.17
Low $86High $125
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 21 | Truist Financial | — | — |
| Sep 16 | Wells Fargo | $86 | +42.2% |
| Sep 11 | Truist Financial | — | — |
| Sep 10 | BMO Capital | $100 | +65.3% |
| Sep 10 | Leerink Partners | $100 | +65.3% |
+3.1%average 20-day move after past Buying readings
+13.6%average move over the next 20 trading days in the last 5 years
±4.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Disc Medicine seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Disc Medicine averaged +13.6% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +6.6% | 3 of 5 |
| Next 10 trading days | +5.8% | 4 of 5 |
| Next 15 trading days | +6.4% | 3 of 5 |
| Next 20 trading days | +13.6% | 5 of 5 |
| Next 30 trading days | +10.8% | 3 of 5 |
For scale, IRON’s typical 20-trading-day move in either direction is about 10.2%.
Disc Medicine market cap and key statistics
Disc Medicine’s market cap is $2.32B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $2.32B
- EPS, TTM
- −$6.58
- Gekko Fair Value
- $78.34
Trading
- Volume
- 648,354
- Avg volume, 20 days
- 644,868
- 52-week high
- $99.50
- 52-week low
- $40.00
- Shares outstanding
- 38.39M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -39.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.11
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±10.2%
Disc Medicine stock news this week
5 headlines about Disc Medicine from the past week, newest first, each linking to the publisher.
- Disc Medicine Q3 2026 Earnings Date and EstimatesMarketBeat, Oct 10
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONNewsfile Corp, Oct 7
- Disc Medicine Investor News: If You Have Suffered Losses inGlobeNewswire, Oct 6
- ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONNewsfile Corp, Oct 6
- Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewsWire, Oct 5
Disc Medicine peers
Disc Medicine’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Disc Medicine stock FAQ
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $2.32B at the Oct 12, 2026 close of $60.48, with 38.39M shares outstanding.
What is the Disc Medicine stock forecast?
The consensus analyst 12-month price target for Disc Medicine is $103.17, +70.6% from the last close. Of the 11 firms that rated the stock in the last 90 days, 11 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Disc Medicine stock overvalued or undervalued?
On Gekko’s estimate Disc Medicine is undervalued: the Oct 12, 2026 close of $60.48 is 22.8% below Gekko Fair Value of $78.34. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Disc Medicine report earnings next?
Disc Medicine is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of −$1.63 per share on revenue of $1.88M. Disc Medicine beat the earnings estimate in 5 of its last 8 reports, moving 3.2% on average across the report.
What is Disc Medicine’s 52-week high and low?
Disc Medicine’s 52-week high is $99.50 and its 52-week low is $40.00; it closed at $60.48 on Oct 12, 2026, −14.5% over the past year.
Is Disc Medicine stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Disc Medicine the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.